News

Here's what is coming soon to NeurologyLive.

The founder and chief scientific officer of Neurolutions discussed the clinical tools that make up the IpsiHand Upper Extremity Rehabilitation System and the benefits it brings.

The trial will be the first neuroimaging study aimed at observing the impacts of rhythmic auditory stimulation on walking impairment in multiple sclerosis.

A recent paper supported by several presentations at AAN 2021 elucidate areas of migraine care to improve.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his investigations into improving the MSPT.

The findings suggest that patients with dementia should be prioritized for stringent preventive measures, greater surveillance, and early intervention in COVID-19.

Neurology News Network for the week ending May 22, 2021.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed the organization’s ultimate goal of curing MS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

Marian LaMonte, MD, MSN, FAAN, chief of neurology at Ascension Saint Agnes, discussed her team’s efforts to improve compliance in providing stroke discharge instructions.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the barriers to the use of preventive medicines.

The county with the highest premature stroke mortality was 20.78 times higher than that of the county with the lowest mortality. The data have raised alarms among the study authors.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Matthew B. Harms, MD.

A budget impact analysis suggested that Cala Health’s Cala Trio device can serve as a cost-saving treatment option for patients with ET.

Environmental factors such as smoking, alcohol consumption, overweight/obese status, and sun exposure were associated with an increased risk of relapsing-onset and progressive-onset MS.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed the importance of correcting practice effects to determine performance.

Only 4.9% of respondents in active clinical practice at the time of the survey reported not using telehealth when providing patient care services.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed future ideas for the MANAGE-PD tool to furthering its benefits.

Vineet Punia, MD, MS, shared thoughts on his study from AAN 2021 which characterized generalized epilepsy in older adults and the elderly, and raised questions about its overall prevalence.

Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.

Jason Poon, MD, neurologist at University of Utah, discussed his study on diagnostic accuracy in telestroke consultations.

The trial design was presented at the 2021 ENCALS meeting and is set to run for 48 weeks at more than 50 clinical centers.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the development of the aT2-LV biomarker.

Migraine with aura was associated with the risk of incident hypertension and no significant difference was observed between individuals with or without aura.

The director of research at St. Luke’s Sleep Medicine and Research Center discussed the current treatment landscape for excessive daytime sleepiness and how solriamfetol plays a role.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

Acute encephalopathy, coma, and stroke were among clinically diagnosed neurological symptoms that increased mortality risk in patients with COVID-19.

The investigational drug, previously granted fast-track designation, did not meet primary or secondary end points in the ORARIALAS-01 trial.

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed the potential of the mobile toolbox battery to screen hundreds of thousands for cognitive impairment.

The degree of increased risk for subsequent ischemic events following intracerebral hemorrhage persisted after adjusting for basic demographic characteristics and traditional vascular risk factors.